Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten ye...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies fo...
Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investor...
Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.33) per share. This is a 8.9 percent increase over losses of $(1...
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the...
Upgrades
Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter:
